HbA1c and beyond

Forskning

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

HbA1c and beyond. / Rossing, Peter.

I: Nephrology Dialysis Transplantation, Bind 38, Nr. 1, 2023, s. 34-40.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Rossing, P 2023, 'HbA1c and beyond', Nephrology Dialysis Transplantation, bind 38, nr. 1, s. 34-40. https://doi.org/10.1093/ndt/gfab243

APA

Rossing, P. (2023). HbA1c and beyond. Nephrology Dialysis Transplantation, 38(1), 34-40. https://doi.org/10.1093/ndt/gfab243

Vancouver

Rossing P. HbA1c and beyond. Nephrology Dialysis Transplantation. 2023;38(1):34-40. https://doi.org/10.1093/ndt/gfab243

Author

Rossing, Peter. / HbA1c and beyond. I: Nephrology Dialysis Transplantation. 2023 ; Bind 38, Nr. 1. s. 34-40.

Bibtex

@article{d8a25fa1c5f24369ac8710681f92694b,

title = "HbA1c and beyond",

abstract = "The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on Diabetes Management in Chronic Kidney Disease from 2020 comes at an opportune time when progress in diabetes technology and therapeutics offers new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. Management of haemoglobin A1c is important in diabetes, but an enlarging base of evidence from large clinical trials has demonstrated important new treatments offering organ protection and not just glucose management, such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. It is the ambition that the guideline can help to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies based on high-quality evidence. Here, the focus has been on comprehensive care of patients with diabetes and CKD, glycaemic monitoring and targets, antihyperglycaemic therapies in patients with diabetes and CKD, and new developments since the guideline was published offering new opportunities and a wider target population for the new interventions. ",

keywords = "chronic kidney disease, diabetes, guideline, HbA1c, KDIGO",

author = "Peter Rossing",

year = "2023",

doi = "10.1093/ndt/gfab243",

language = "English",

volume = "38",

pages = "34--40",

journal = "Nephrology, Dialysis, Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "1",

}

RIS

TY - JOUR

T1 - HbA1c and beyond

AU - Rossing, Peter

PY - 2023

Y1 - 2023

N2 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on Diabetes Management in Chronic Kidney Disease from 2020 comes at an opportune time when progress in diabetes technology and therapeutics offers new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. Management of haemoglobin A1c is important in diabetes, but an enlarging base of evidence from large clinical trials has demonstrated important new treatments offering organ protection and not just glucose management, such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. It is the ambition that the guideline can help to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies based on high-quality evidence. Here, the focus has been on comprehensive care of patients with diabetes and CKD, glycaemic monitoring and targets, antihyperglycaemic therapies in patients with diabetes and CKD, and new developments since the guideline was published offering new opportunities and a wider target population for the new interventions.

AB - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on Diabetes Management in Chronic Kidney Disease from 2020 comes at an opportune time when progress in diabetes technology and therapeutics offers new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. Management of haemoglobin A1c is important in diabetes, but an enlarging base of evidence from large clinical trials has demonstrated important new treatments offering organ protection and not just glucose management, such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. It is the ambition that the guideline can help to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies based on high-quality evidence. Here, the focus has been on comprehensive care of patients with diabetes and CKD, glycaemic monitoring and targets, antihyperglycaemic therapies in patients with diabetes and CKD, and new developments since the guideline was published offering new opportunities and a wider target population for the new interventions.

KW - chronic kidney disease

KW - diabetes

KW - guideline

KW - HbA1c

KW - KDIGO

U2 - 10.1093/ndt/gfab243

DO - 10.1093/ndt/gfab243

M3 - Review

C2 - 34383945

AN - SCOPUS:85151613732

VL - 38

SP - 34

EP - 40

JO - Nephrology, Dialysis, Transplantation

JF - Nephrology, Dialysis, Transplantation

SN - 0931-0509

IS - 1

ER -

ID: 366985837